The consensus of experts of the russian association for osteoporosis on the long-term treatment of osteoporosis with bisphosphonates

   Bisphosphonates are the most commonly used drugs for the treatment of osteoporosis and reducing the risk of fractures, which were introduced into clinical practice more than 30 years ago. The bisphosphonate group includes oral (alendronic acid, risedronic acid, ibandronic acid) and parenteral (zoledronic acid, ibandronic acid) preparations. By now, quite large groups of patients with osteoporosis have been taking bisphosphonates for a long time. This fact raises questions about the preservation of the clinical effect, the development of side effects of drugs against the background of prolonged administration, as well as the possibility of cessation or interruption in their use. The document contains recommendations of the experts of the Russian Association for Osteoporosis on the management of patients with osteoporosis receiving bisphosphonate therapy based on the literature review and discussion. The recommended duration of treatment with oral and parenteral bisphosphonates, methods for monitoring the effectiveness of treatment, as well as signs that should be used when deciding on a discontinuation of the therapy or an increase in its duration are formulated. The criteria of ineffectiveness of treatment requiring its correction are discussed. A separate section is devoted to monitoring the patient during a ‘drug holiday’ in taking bisphosphonates and making a decision on resuming treatment. Recommendations are also given for the control and prevention of possible side effects and increasing persistence to bisphosphonate treatment.

1. Lesnyak OM, Baranova IA, Belova KYu, et al. Osteoporosis in Russian Federation: Epidemiology, Socio-Medical and Economical Aspects (Review). Traumatology and Orthopedics of Russia. 2018;24(1):155-168. (in Russ.)]. doi: 10.21823/2311-2905-2018-24-1-155-168

2. [Marchenkova LA, Vasileva VA. Long-term therapy with bisphosphonates: review of clinical studies. Osteoporosis and Bone Diseases. 2023;26(4):4-7. (In Russ.). doi: 10.14341/osteo13143

3. Nikitinskaya O.A. Long-term consequences of osteoporosis therapy with bisphosphonates. Osteoporosis and Bone Diseases. 2023;26(4):14-19. (In Russ.). doi: 10.14341/osteo13148

4. Dudinskaya EN, Malaya IP. Deprescribing bisphosphonates in the osteoporosis treatment in older people. Osteoporosis and Bone Diseases. 2023;26(4):26-33. (In Russ.). doi: 10.14341/osteo13155

5. Fominykh MI, Evstigneeva LP. Review of recommendations for bisphosphonate treatment interruption-discontinuation. Osteoporosis and Bone Diseases. 2023;26(4):8-13. (In Russ.). doi: 10.14341/osteo13146

6. Belova KY, Ershova OB, Skripnikova IA. Results of bisphosphonate withdrawal: duration of antiresorptive activity, fractures, changes in BMD and bone turnover markers. Osteoporosis and bone diseases. 2023;26(3):18-24. (in Russ.) doi: 10.14341/osteo13145

7. Toroptsova NV, Baranova IA. Current vision on mechanism of action of bisphosphonates. The effect of long-term administration of bisphosphonates on bone tissue (preclinical studies). Osteoporosis and bone diseases. 2023;26(3):4-11. (in Russ.) doi: 10.14341/osteo13147

8. Shkireeva SU, Lesnyak OM. Long-term treatment with bisphosphonates in clinical practice: advantages, main problems and risks. Osteoporosis and bone diseases. 2023;26(3):12-17. (in Russ.) doi: 10.14341/osteo13157

9. Belaya Zh., Rozhinskaya LYa. Surrogate markers in assessment of bisphosphonate effectiveness in osteoporosis treatment (bone mineral density, bone turnover markers). Osteoporosis and Bone Diseases. 2023;26(4):20-25. (In Russ.). doi: 10.14341/osteo13166

10. Yureneva SV, Averkova VG. Bisphosphonates for the prevention of osteoporotic fractures in postmenopausal women with osteopenia: a systematic review and meta- analysis. Osteoporosis and bone diseases. 2024;27(1):21-34. doi: 10.14341/osteo13150

11. Mazurov VI, Lesnyak OM, Belova KIu, et al. Algorithm for selection of drug for osteoporosis treatment in primary care and in organization of provision with medicinal products of citizens eligible for state social assistance. Review of the literature and position of Russian Association on Osteoporosis Expert Council. Profilakticheskaya Meditsina. 2019;22(1):5765. (In Russ.)] doi: 10.17116/profmed20192201157